Where AdaptHealth Stands With Analysts
Analysts have provided the following ratings for AdaptHealth (NASDAQ:AHCO) within the last quarter:
Susquehanna Slashes Price Target On NetApp, Plus Compass Point Boosts PT On This Stock By 75%
Susquehanna cut the price target on NetApp, Inc. (NASDAQ: NTAP) from $100 to $75. Susquehanna analyst Mehdi Hosseini also downgraded the stock from Positive to Neutral. NetApp shares fell 1.3% to trade at $67.76 on Monday.
RBC Capital Maintains Outperform on AdaptHealth, Raises Price Target to $29
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and raises the price target from $26 to $29.
Micron Technology, Novavax, CarGurus And Some Other Big Losers From Tuesday
U.S. stocks closed lower, with the Nasdaq dropping 150 points on Tuesday. Here is the list of some big stocks moving lower in the previous session.
SVB Leerink Maintains Outperform on AdaptHealth, Raises Price Target to $29
SVB Leerink analyst Whit Mayo maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and raises the price target from $24 to $29.
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
AdaptHealth Maintains FY22 Guidance
Guidance Maintained for Fiscal Year 2022
The Company is maintaining its previously issued financial guidance for fiscal year 2022, as follows:
Net revenue of $2.840 billion to $3.040
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million.
Truist Securities Maintains Buy on AdaptHealth, Raises Price Target to $24
Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and raises the price target from $20 to $24.